BACKGROUND: An understanding of the humanistic and economic burden of individuals with symptomatic chronic obstructive pulmonary disease (COPD) is required to inform payers and healthcare professionals about the disease burden. OBJECTIVES: The aim of this systematic review was to identify and present humanistic [health-related quality of life (HRQoL)] and economic burdens of symptomatic COPD. METHODS: A comprehensive search of online databases (reimbursement or claims databases/other databases), abstracts from conference proceedings, published literature, clinical trials, medical records, health ministries, financial reports, registries, and other sources was conducted. Adult patients of any race or gender with symptomatic COPD were included. Humanistic and economic burdens included studies evaluating HRQoL and cost and resource use, respectively, associated with symptomatic COPD. RESULTS: Thirty-two studies reporting humanistic burden and 74 economic studies were identified. Symptomatic COPD led to impairment in the health state of patients, as assessed by HRQoL instruments. It was also associated with high economic burden across all countries. The overall, direct, and indirect costs per patient increased with an increase in symptoms, dyspnoea severity, and duration of disease. Across countries, the annual societal costs associated with symptomatic COPD were higher among patients with comorbidities. CONCLUSIONS: Symptomatic COPD is associated with a substantial economic burden. The HRQoL of patients with symptomatic COPD is, in general, low and influenced by dyspnoea.
BACKGROUND: An understanding of the humanistic and economic burden of individuals with symptomatic chronic obstructive pulmonary disease (COPD) is required to inform payers and healthcare professionals about the disease burden. OBJECTIVES: The aim of this systematic review was to identify and present humanistic [health-related quality of life (HRQoL)] and economic burdens of symptomatic COPD. METHODS: A comprehensive search of online databases (reimbursement or claims databases/other databases), abstracts from conference proceedings, published literature, clinical trials, medical records, health ministries, financial reports, registries, and other sources was conducted. Adult patients of any race or gender with symptomatic COPD were included. Humanistic and economic burdens included studies evaluating HRQoL and cost and resource use, respectively, associated with symptomatic COPD. RESULTS: Thirty-two studies reporting humanistic burden and 74 economic studies were identified. Symptomatic COPD led to impairment in the health state of patients, as assessed by HRQoL instruments. It was also associated with high economic burden across all countries. The overall, direct, and indirect costs per patient increased with an increase in symptoms, dyspnoea severity, and duration of disease. Across countries, the annual societal costs associated with symptomatic COPD were higher among patients with comorbidities. CONCLUSIONS: Symptomatic COPD is associated with a substantial economic burden. The HRQoL of patients with symptomatic COPD is, in general, low and influenced by dyspnoea.
Authors: Marianne Voll-Aanerud; Tomas M L Eagan; Tore Wentzel-Larsen; Amund Gulsvik; Per S Bakke Journal: Respir Med Date: 2007-12-03 Impact factor: 3.415
Authors: Mohamed S Al Moamary; Hani M Tamim; Sana S Al-Mutairi; Thamer H Al-Khouzaie; Bassam H Mahboub; Suhaila E Al-Jawder; Omer S Alamoudi; Mohammed O Al Ghobain Journal: Saudi Med J Date: 2012-10 Impact factor: 1.484
Authors: Carlos H Martinez; Alejandro A Diaz; Amit D Parulekar; Stephen I Rennard; Richard E Kanner; Nadia N Hansel; David Couper; Kristen E Holm; Karin F Hoth; Jeffrey L Curtis; Fernando J Martinez; Nicola A Hanania; Elizabeth A Regan; Robert Paine; Christine T Cigolle; MeiLan K Han Journal: Chest Date: 2015-12-17 Impact factor: 9.410
Authors: Radmila Choate; Cara B Pasquale; Nereida A Parada; Valentin Prieto-Centurion; Richard A Mularski; Barbara P Yawn Journal: Chronic Obstr Pulm Dis Date: 2020-01
Authors: Margarethe E Wacker; Rudolf A Jörres; Annika Karch; Sarah Wilke; Joachim Heinrich; Stefan Karrasch; Armin Koch; Holger Schulz; Henrik Watz; Reiner Leidl; Claus Vogelmeier; Rolf Holle Journal: BMC Pulm Med Date: 2016-05-10 Impact factor: 3.317
Authors: Jason Foo; Sarah H Landis; Joe Maskell; Yeon-Mok Oh; Thys van der Molen; MeiLan K Han; David M Mannino; Masakazu Ichinose; Yogesh Punekar Journal: PLoS One Date: 2016-04-19 Impact factor: 3.240
Authors: Victoria Austin; Peter J Crack; Steven Bozinovski; Alyson A Miller; Ross Vlahos Journal: Clin Sci (Lond) Date: 2016-07-01 Impact factor: 6.124